Rebound effects caused by withdrawal of MET Kinase inhibitor are quenched by a MET Therapeutic antibody

Cancer Research

Volumn 76, Issue 17, 2016, Pages 5019-5029

  Pupo, Emanuela ^a   Ducano, Nadia ^a   Lupo, Barbara ^b,c   Vigna, Elisa ^b,c   Avanzato, Daniele ^a   Perera, Timothy ^d   Trusolino, Livio ^b,c   Lanzetti, Letizia ^a,c   Comoglio, Paolo M ^b,c  

^a IRCCS   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Octimet Oncology Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTIBODY; CRIZOTINIB; JNJ 605; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOVALENT ANTIBODY DN30; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG WITHDRAWAL; ENDOCYTOSIS; ENDOSOME; EXPERIMENTAL NEOPLASM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; REBOUND; ANIMAL; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR RECURRENCE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, CONFOCAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84985916033     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3107     Document Type: Article

References (31)

1. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
2. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2:289-300.
3. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
4. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109:863-7.
5. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
6. Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2009;2:er11.
7. Serio G, Margaria V, Jensen S, Oldani A, Bartek J, Bussolino F, et al. Small GTPase Rab5 participates in chromosome congression and regulates localization of the centromere-associated protein CENP-F to kinetochores. Proc Natl Acad Sci U S A 2011;108:17337-42.
8. Roberts M, Barry S, Woods A, van der Sluijs P, Norman J. PDGFregulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr Biol 2001;11:1392-402.
9. Palamidessi A, Frittoli E, Ducano N, Offenhauser N, Sigismund S, Kajiho H, et al. The GTPase-activating protein RN-tre controls focal adhesion turnover and cell migration. Curr Biol 2013;23:2355-64.
10. Fu L, Medico E. FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data. BMC Bioinformatics 2007;8:3.
11. Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 2010;285:36149-57.
12. Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilico C, Petronzelli F, et al. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.Mol Oncol 2015;9:1760-72.
13. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8.
14. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998;111:237-47.
15. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103:2316-21.
16. Ferracini R, Longati P, Naldini L, Vigna E, Comoglio PM. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. J Biol Chem 1991;266:19558-64.
17. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6:61-73.
18. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004; 6:75-84.
19. Sangwan V, Paliouras GN, Abella JV, Dube N, Monast A, Tremblay ML, et al. Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase. J Biol Chem 2008;283:34374-83.
20. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene 1994;9:49-57.
21. Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 1994;9:2019-27.
22. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 2006;103:5090-5.
23. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFRmutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17:6298-303.
24. Kuriyama Y, Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M. Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinasepositive lung cancer. Case Rep Oncol 2013;6:430-3.
25. West H, Oxnard GR, Doebele RC. Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents. Am Soc Clin Oncol Educ Book 2013. p. e272-8.
26. Sangwan V, Abella J, Lai A, Bertos N, Stuible M, Tremblay ML, et al. Proteintyrosine phosphatase 1B modulates early endosome fusion and trafficking of Met and epidermal growth factor receptors. J Biol Chem 2011;286: 45000-13.
27. Joffre C, Barrow R, Menard L, Calleja V, Hart IR, Kermorgant S. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 2011;13:827-37.
28. Parachoniak CA, Luo Y, Abella JV, Keen JH, Park M. GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev Cell 2011;20:751-63.
29. Muharram G, Sahgal P, Korpela T, De Franceschi N, Kaukonen R, Clark K, et al. Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells. Dev Cell 2014;29:421-36.
30. Barrow-McGee R, Kermorgant S. Met endosomal signalling: in the right place, at the right time. Int J Biochem Cell Biol 2014;49:69-74.
31. Martin V, Corso S, Comoglio PM, Giordano S. Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. Mol Oncol 2014;8:1561-74.